Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fujifilm Diosynth Biotechnologies Announces Strategic Alliance with Piramal Healthcare

Published: Thursday, October 25, 2012
Last Updated: Wednesday, October 24, 2012
Bookmark and Share
Strategic alliance for the production of antibody drug conjugates.

Fujifilm Diosynth Biotechnologies has announced that it has entered into a strategic alliance with Piramal Healthcare UK Ltd, whereby the two parties will offer the seamless contract development and manufacture of antibody drug conjugates (ADCs), a growing niche in the development of biopharmaceuticals.

The deal will allow customers to benefit from the experience and assets of both organizations, while simplifying the supply chain and vendor management relationships, leading to shorter time to clinic.

Fujifilm Diosynth Biotechnologies is one of the world's leading providers of contract development and manufacturing services for biopharmaceuticals, whilst Piramal is a world leader in antibody drug conjugation.

The combined experience covers work on more than 150 biopharmaceuticals and over 300 batches of ADCs spanning over more than 30 different NCEs, including the world's only FDA-approved ADC.

For Fujifilm Diosynth Biotechnologies, this is part of an ongoing programme to expand its offering in mammalian-based biopharmaceuticals.

The company recently announced an expansion of its cGMP manufacturing facilities at both its RTP, USA and Billingham, UK sites.

Stephen Taylor, Commercial Vice President of Fujifilm Diosynth Biotechnologies said "This strategic alliance with Piramal is an important step for us in bringing a new, high-technology offering to the market place. Our customers will benefit from high quality, consistent material, rapid service and shorter logistical chains, saving time on the critical path of drug development. Piramal is a recognized world-leader in this area and we are delighted to be partnering with them".

Aidan Walker, President Formulations Services, Piramal said "We are delighted to combine with Fujifilm Diosynth Biotechnologies to offer a seamless service to customers for the production of antibody conjugates. Fujifilm Diosynth Biotechnologies has a long track-record in delivering successful biologics programmes, and this alliance will combine strengths from both companies for the benefit of our customers, and ultimately patients".


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Fujifilm Diosynth Announces Collaboration on a New 20,000-Liter Microbial Biologics Facility
Company has announced collaboration with MSD to invest in and operate a large-scale microbial-biologics facility for supply of active pharmaceutical ingredient (API) to its customers.
Tuesday, June 07, 2016
FUJIFILM Completes Acquisition of Kalon Biotherapeutics
Acquisition enhances Texas’ growing reputation as a global biotechnology leader.
Friday, December 19, 2014
Fujifilm Diosynth Biotechnologies Expands Cell Culture Manufacturing Capacity
The company expands capabilities with the addition of two new 2,000l single-use bioreactors.
Tuesday, August 19, 2014
Fujifilm Diosynth Biotechnologies Continues Expansion of R&D Facilities
Company invests more than US$5.6M in new laboratories and equipment.
Wednesday, June 25, 2014
Fujifilm Diosynth Biotechnologies’ UK Site Receives Renewed Manufacturing Licence
Licence authorizes commercial manufacturing at the company’s Billingham, UK site.
Thursday, October 10, 2013
Fujifilm Diosynth Biotechnologies Manufactures a New Licensed Biopharmaceutical
ThromboGenics' has received FDA approval for the launch of JETREA® in the USA.
Thursday, November 15, 2012
Fujifilm Diosynth Expands R&D Capabilities at its Billingham, UK Site
Company has completed the first phase of a $4.5m investment in new equipment and laboratories.
Friday, April 06, 2012
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Manufactured Stem Cells to Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Gender Determination in Forensic Investigations
This study investigated the effectiveness of lip print analysis as a tool in gender determination.
Identifying Novel Types of Forensic Markers in Degraded DNA
Scientists have tried to verify the nucleosome protection hypothesis by discovering STRs within nucleosome core regions, using whole genome sequencing.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Starving Stem Cells May Enable Scientists To Build Better Blood Vessels
Researchers from the University of Illinois at Chicago College of Medicine have uncovered how changes in metabolism of human embryonic stem cells help coax them to mature into specific cell types — and may improve their function in engineered organs or tissues.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!